Find the right fit for you - faster
Get tailored insights about working at Gamma Medica in one quick step.
Gamma Medica Snapshot
Gamma Medica is committed to providing peace of mind to patients and physicians alike through the use of MBI as a secondary screening and diagnostic tool.
Gamma Medica, Inc. is a women’s health company focused on overcoming the limitations of anatomical imaging used by mammography and other screening modalities in the early detection of breast cancer. The company’s LumaGEM® MBI system is the first commercially available, FDA-approved, fully solid-state digital imaging system utilizing dual-head Digital Direct Conversion Gamma Imaging™ (DDCGI™) technology for molecular breast imaging. With over 90-percent sensitivity and specificity, LumaGEM MBI has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound. For more information visit, www.gammamedica.com.
